Tumour Registry Colorectal Cancer (TKK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00910819
Recruitment Status : Active, not recruiting
First Posted : June 1, 2009
Last Update Posted : August 22, 2017
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):

May 28, 2009
June 1, 2009
August 22, 2017
September 2006
March 2020   (Final data collection date for primary outcome measure)
Course of Antineoplastic Treatment [ Time Frame: 5 years ]
Same as current
Complete list of historical versions of study NCT00910819 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Tumour Registry Colorectal Cancer
Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.

The TKK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of colorectal cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (CoNut) and physical activity (CoNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (CoTox) and the final phase of the palliative process (CoLife). Based on the available data a prognostic score will be developed.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Colorectal cancer patients undergoing antineoplastic treatment.
Colorectal Cancer
Not Provided
Not Provided
Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clin Epidemiol. 2015 Apr 20;7:295-303. doi: 10.2147/CLEP.S73857. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
March 2020
March 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Colorectal cancer
  • 18 years and older
  • Antineoplastic treatment

Exclusion Criteria:

  • No colorectal cancer
  • Below 18 years
  • No antineoplastic treatment
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Plan to Share IPD: No
  • Arbeitskreis Klinische Studien
  • Arbeitsgemeinschaft fur Internistische Onkologie
Study Chair: Roland Schnell, MD
August 2017